Skip to content

Health Belief Model-Based Telenursing for Hypertension

The Effect of Health Belief Model-Based Interventions Delivered Via Telenursing to Individuals Diagnosed With Hypertension on Hypertension Self-Efficacy and Quality of Life

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07823257
Enrollment
78
Registered
2026-09-16
Start date
2024-07-09
Completion date
2025-02-28
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Telenursing, Health Belief Model, Self-Efficacy, Quality of Life, Blood Pressure, Nursing

Brief summary

This randomized controlled trial evaluated the effects of a Health Belief Model-based telenursing intervention on self-efficacy, quality of life, blood pressure, body mass index, and health behaviors in individuals with hypertension. A total of 78 participants were randomly assigned to the intervention group (n=39) or control group (n=39). Participants in the intervention group received a 12-week telenursing intervention based on the Health Belief Model, including face-to-face education, training on home blood pressure monitoring, educational materials, weekly text messages, and telephone follow-up at weeks 2, 4, 8, and 12. The control group received usual care. Outcomes were assessed at baseline, 3 months, and 6 months.

Interventions

BEHAVIORALHealth Belief Model-Based Telenursing Intervention

The intervention consisted of Health Belief Model-based education and a 12-week telenursing follow-up program. Participants received four telephone follow-up calls at weeks 2, 4, 8, and 12, each lasting approximately 10-15 minutes. Weekly text messages were sent for 12 weeks to remind participants about blood pressure monitoring and to provide information about hypertension management. Participants could also contact the researcher when they needed additional support.

Sponsors

Marmara University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Participants were not informed whether they were assigned to the intervention or control group.

Eligibility

Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Aged 30-65 years * Diagnosed with hypertension by a physician * No cognitive or hearing impairments that could hinder communication * Literate * Using a mobile phone * Willing to participate in the study

Exclusion criteria

* Did not respond to scheduled telephone calls for at least two consecutive weeks * Transferred registration to another Family Health Center * Voluntarily withdrew from the study

Design outcomes

Primary

MeasureTime frameDescription
Hypertension Self-EfficacyBaseline, 3 months, and 6 monthsHypertension self-efficacy was assessed using the Hypertension Self-Efficacy Scale (HSES). The scale consists of 20 items, with higher scores indicating higher hypertension self-efficacy.
Health-Related Quality of LifeBaseline, 3 months, and 6 monthsHealth-related quality of life was assessed using the 12-Item Short Form Health Survey (SF-12), which provides Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Higher scores indicate better health-related quality of life.

Secondary

MeasureTime frameDescription
Systolic Blood PressureBaseline, 3 months, and 6 monthsSystolic blood pressure was measured in mmHg. Blood pressure measurements were obtained to evaluate changes in systolic blood pressure during the study.
Diastolic Blood PressureBaseline, 3 months, and 6 monthsDiastolic blood pressure was measured in mmHg. Blood pressure measurements were obtained to evaluate changes in diastolic blood pressure during the study.
Body Mass IndexBaseline, 3 months, and 6 monthsBody mass index (BMI) was calculated as body weight in kilograms divided by height in meters squared (kg/m²).

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026